Previous 10 | Next 10 |
The following slide deck was published by Athersys, Inc. in conjunction with this event. For further details see: Athersys (ATHX) Investor Presentation Treasure Data - Slideshow
Athersys (NASDAQ:ATHX) stock fell ~19% on May 23 after Bank of America downgraded the shares to Underperform from Neutral, following failure of a Japanese trial of MultiStem for ischemic stroke, and risks related to outcome of another U.S. study. Bank of America analyst Gr...
Announcing topline data from a Japan-based trial for its MultiStem cell therapy candidate in ischemic stroke, the clinical-stage biotech Athersys (NASDAQ:ATHX) said on Friday that the 206-patient study did not reach the primary endpoint with statistical significance. Athersys (ATHX) has ...
TREASURE topline results show evidence of therapeutic impact Study preliminary results analyses indicate good potential for favorable results in Athersys’ MASTERS-2 study Conference call today at 8:30 a.m. ET Athersys, Inc. (Nasdaq: ATHX) a...
TREASURE topline results show evidence of therapeutic impact Study preliminary results analyses indicate good potential for favorable results in Athersys’ MASTERS-2 study Conference call today at 8:30 a.m. ET Athersys, Inc. (Nasdaq: ATHX) a...
Penny stocks are shares of companies trading for less than $5 per share. They’re inherently volatile, and they tend to perform unrelated to broader trends in times of market uncertainty. While this isn’t the case for all penny stocks , you’re sure to find at least a...
Athersys, Inc. (Nasdaq: ATHX), announced today that Dan Camardo, Chief Executive Officer, will participate virtually in the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, Florida. The Company’s management team will also participate in one-on-one...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks have been through an extended lean patch, making them ideal candidates for a strong rebound. Verrica ( VRCA ): Approval of its viral skin disease treatment could transform the company into a commerci...
3 Hot Penny Stocks That Investors Are Watching Right Now As we end another week of trading penny stocks, there is a lot that investors need to know. The stock market is ever-changing, and it can be tough to keep up with the constant flux. However, by understanding what is going on with ...
Athersys press release (NASDAQ:ATHX): Q1 GAAP EPS of -$0.09 in-line. Revenue of $2.91M beats by $1.53M. “Receiving FDA approval to use the bioreactor manufactured product gives us confidence as we further scale our third-generation bioreactor manufacturing process to be able to produce...
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...